GENE ONLINE|News &
Opinion
Blog

2022-01-06| COVID-19Technology

Celltrion’s New Antibody Is Effective against the Omicron Variant

by Sahana Shankar
Share To

Vaccines have been the most powerful weapon to combat the Covid-19 pandemic. However, breakthrough infections of the Delta and Omicron variants in double-vaccinated people suggest that we need a diverse arsenal of antivirals to offer protection from the SARS-CoV-2 virus. All major pharma companies are working on multiple candidates to develop treatments which are effective against existing and possibly emerging variants. 

South Korea- based Celltrion Healthcare introduced a cocktail therapy candidate for effective therapy against the Omicron variant. 

 

Combating the threat from emerging Covid variants

 

CT-P63, a monoclonal antibody against the viral spike’s receptor binding domain (RBD), was successfully tested for safety, efficacy and tolerance in Phase I randomised, double-blind and placebo-controlled clinical trial, without any significant adverse events. Crystal structure and cell-based analyses conducted in collaboration with the U.S National Institutes of Health studied the antibody’s interaction with the virus demonstrated strong neutralisation of the Omicron variant. Further data on animal models and neutralising titres in wider cell biology studies are expected in the next few months.  

The clinical trial, conducted in Poland, enrolled 24 healthy participants to test the pharmacokinetic profile of CT-P63. Previous studies showed that CT-P63 is effective in neutralising the Alpha, Beta, Gamma and Delta variants of SARS-CoV-2. 

 

Celltrion’s anti-Covid pipeline

 

Celltrion has a candidate list of 38 antibodies which are being tested for effective antiviral activity against Covid variants, with plans to evaluate them for neutralisation of new emerging variants tailored to specific regions and assess potential escape mutants by using in vitro pseudo-virus assay. At the Korea Bio Investment Conference 2021, Senior Managing Director, Lee Soo Young introduced  Regkirona (CT-P59), a monoclonal antibody therapy against coronavirus, which was approved by the European Medicines Agency (EMA) and is under review with the U.S. FDA. Previously, Celltrion bagged approval for its Covid rapid testing kit, DiaTrust and is available for at-home testing. 

Celltrion aims to develop cocktail therapy options by combining CT-P63 and Regkirona nebuliser treatments for at-home patients using their patented nebuliser formulation, while the monoclonal antibody treatments are recommended for hospitalised patients. “The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Gilead Spends $405 Million In Cash to Acquire MiroBio
2022-08-05
Moderna to Supply 66 Million COVID-19 Boosters to US
2022-07-29
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!